Royalty Pharma Withdraws Elan Bid


Jun 20, 2013

The New York Times

Following a fierce four-month acquisition battle, Royalty Pharma has dropped its takeover offer of $6.7 billion for Irish drug company Elan. Trouble over shareholder votes and share buyback plans caused issues in the takeover process. As a result, Royalty Pharma announced they would no longer pursue the judical review initially requested. Elan's future now remains uncertain. The company put itself up for sale last week. Read the full story.
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments